Authors
Latest:
Breast Density in Black Versus White WomenAnne Marie McCarthy, PhD, research fellow, Massachusetts General Hospital, discusses a study that examined breast density, a risk that can help target breast cancer, in black women compared to white women.
Latest:
Future Targeted Therapy Approaches in NSCLCAnne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.
Latest:
G-CSF Use Maintains Effective Docetaxel Dose in ARASENS Regimen for mHSPCG-CSF plus docetaxel modification allowed almost all patients with mHSPC to receive an efficacious dose of docetaxel plus darolutamide/ADT.
Latest:
Dr. Elias Discusses the Future of Androgen Receptors in Breast CancerAnthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado Denver, discusses the future of androgen receptors in breast cancer.
Latest:
Sequencing Therapy in the Current Treatment Landscape of CholangiocarcinomaAnthony El-Khoueiry, MD, provides a brief review of sequencing therapy for patients with cholangiocarcinoma in the modern treatment landscape.
Latest:
Patient With a PIK3CA-Positive Tumors Exhibits Hyperglycemia Associated With AlpelisibThe approval of alpelisib in May 2019 poses a challenge to oncologists and their practices with the emergence of hyperglycemia as an AE associated with PI3K inhibitors. Managing the patient effectively requires a multidisciplinary team approach that involves counseling up front, monitoring throughout the course of therapy, and input and feedback from the team of oncologists, advanced practice providers, pharmacists, and dietitians.
Latest:
The Role of the Pathologist During Melanoma TreatmentAnthony M. Magliocco, MD, discusses the pathologist’s role when treating a patient with melanoma.
Latest:
Limited Following of Best Practices for CLL Observed in the Real-World SettingAnthony Mato, MD, MSCE, discusses an observational registry study of real-world prognostic biomarker testing, treatment patterns and treatment dosing in a pool of 1461 patients with either chronic lymphocytic leukemia.
Latest:
Immune Checkpoint Blockade: A New Strategy for the Treatment of Breast CancerBreast cancer has traditionally not been viewed as immunogenic. There is now a growing body of evidence that immune infiltration has a prognostic role in al breast cancer subtypes, and predicts improved clinical outcome in triple-negative and human epidermal growth factor receptor 2-positive tumors.
Latest:
Sequencing Agents for the Treatment of Patients With MelanomaAntoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses how to appropriately sequence therapies for patients with melanoma.
Latest:
Niraparib Maintenance Improves PFS in Frontline Ovarian CancerAntonio Gonzalez Martín, MD, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.
Latest:
The Role of the ID2 Protein in Brain CancerAntonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.
Latest:
One Expert's Vision for Breast Cancer Treatment in the Next 5 to 10 YearsAntonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses his vision for breast cancer treatment in the next 5 to 10 years.
Latest:
Overcoming Resistance to Agents Treating BRAF Mutations in Colorectal CancerPrecision and personalized medicine targeting driver mutations has revolutionized cancer care in the past decade. Targeted therapy has entered the world of colorectal cancer research with the identification of mutations in KRAS and BRAF genes.
Latest:
The Impact of Darolutamide on Dose Modification of mHSPCArash Rezazadeh Kalebasty, MD, discusses the dose modification impact of the addition of darolutamide for patients with metastatic hormone sensitive prostate cancer.
Latest:
New Combination Builds Upon Existing Therapies for Anaplastic AstrocytomaArati Desai, MD, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma.
Latest:
Emerging Therapies for the Treatment of Mantle Cell LymphomaAri M. Melnick, MD, from Weill Cornell Medical College, comments on emerging therapies for the treatment of mantle cell lymphoma.
Latest:
The Challenges of Measuring Tumor HeterogeneityAri Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses the challenges associated with measuring tumor heterogeneity.
Latest:
Immunoscore Provides Risk Assessments for All Stages of Colon CancerIn a presentation at the 33<sup>rd</sup> Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cance, Dr. Galon discussed the definition of the immune contexture of Immunoscore, its international validation for the risk-classification of stage I-III colon cancer, and the potential value of Immunoscore in stage IV metastatic disease.
Latest:
Results for First-Line Pembrolizumab in Advanced Urothelial CarcinomaArjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discusses biomarker findings and mature clinical results from KEYNOTE-052, which explored first-line pembrolizumab (Keytruda) in cisplatin-ineligible advanced urothelial carcinoma.
Latest:
MRD Assay Is New Step in Urothelial Cancer TestingA post hoc analysis from the IMvigor010 study evaluating circulating tumor ctDNA in patients receiving adjuvant atezolizumab in high-risk muscle-invasive urothelial cancer after surgery was presented at the European Society of Medical Oncology Immuno-Oncology Virtual Congress in 2020.
Latest:
Unlocking the Potential of Erdafitinib in Bladder Cancer TreatmentArlene O. Siefker-Radtke, MD, discusses the latest breakthroughs in bladder cancer treatment with erdafitinib, an FGFR1-4 inhibitor.
Latest:
Dr. Arlene Sharpe on the Discovery and Further Use of the PD-L1 PathwaySharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.
Latest:
Challenges Facing Geriatric Patients With Breast CancerArti Hurria, MD, director, Cancer and Aging Research Program, City of Hope, discusses challenges facing geriatric patients with breast cancer.
